Hunter G. DeKoninck, Practice Group Attorney


Hunter focuses his health law practice primarily on Drug Enforcement Administration (DEA) matters, including litigation and regulatory compliance under the Controlled Substances Act (CSA) for clients in the pharmaceutical industry. Specifically, he specializes in areas of anti-diversion practices and suspicious order monitoring for manufacturers and distributors. He also counsels pharmacies and other practitioners on their policies and procedures for the handling of controlled substances. Relatedly, he represents clients through DEA (and other regulatory bodies) investigations associated with concerns of either diversion, record-keeping violations, or other regulatory matters.

Hunter's representative experience includes:

  • Advising large wholesale drug distributors on DEA compliance, School of Medicine (SOM) policies and procedures, customer risk assessment regarding historical purchasing patterns, and other DEA-related matters;
  • Representing wholesale drug distributors in national opioid multidistrict litigation (MDL); and
  • Defending prescribers and dispensers investigated by the DEA, states' attorneys general, and boards of pharmacy.

Legal Services

Education and Honors

  • Indiana University–Maurer School of Law (J.D., 2015)
    • Indiana Journal of Global Legal Studies, Executive Business Editor (2L Outstanding Associate of the Year, 2014)
    • International Law Society (Vice President)
    • Indiana Moot Court Competition Brief-writing Honors (2014)
  • Wake Forest University (B.A., 2012)

Bar Admissions

  • Indiana

Court Admissions

  • U.S. District Court, Northern District of Indiana
  • U.S. District Court, Southern District of Indiana

Professional Recognition

  • Listed in The Best Lawyers in America® "Ones to Watch," Health Care Law, 2021
  • Indiana Super Lawyers® Rising Stars, Business Litigation, 2021